Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

@inproceedings{Mesia2010QualityOL,
  title={Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck},
  author={R Mesia and F Rivera and Andrzej Kawecki and Sylvie Rottey and Ricardo Hitt and Heinz R Kienzer and Didier Cupissol and Dominique de Raucourt and Marco Benasso and Piotr M Koralewski and J.-P. Delord and C Carsten Bokemeyer and Desmond Curran and Alden Gross and J. B. Vermorken},
  booktitle={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010}
}
BACKGROUND A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL). PATIENTS AND METHODS The European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (QLQ-C30) and QLQ-Head and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…